Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomilnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milnacipran SCHEMBL1156056 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL16163256 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL4434769 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL1289763 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL161558 | 1.00 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL8099 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL12027608 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| 1R,2S-Milnacipran SCHEMBL30083111 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Milnacipran SCHEMBL114034 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 | |
| Levomilnacipran SCHEMBL1707471 | 0.99 | SLC6A2 (1.00) | SLC6A2KDM4EMAPK1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| EP-4426686-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | The Regents of the University of California (US) | 2024-09-11 | — | — | EP | claimed |
| US-20230140798-A1 | SYNTHETIC PEPTIDES DIRECTED AGAINST THE METABOTROPIC GLUTAMATE RECEPTOR 5 | LACTOCORE INC (US) | 2023-05-04 | — | — | US | claimed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| CN-115379847-A | Synthetic peptides for modulating metabotropic glutamate receptor 5 | 拉托科公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | claimed |
| US-20220175873-A1 | SYNTHETIC NEUROMODULATORY PEPTIDES | LACTOCORE, INC. | 2022-06-09 | — | — | US | claimed |
| WO-2022056493-A1 | BIOMARKER DRIVEN METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER | INmune Bio, Inc. (US) | 2022-03-17 | — | — | WO | claimed |
| EP-2805936-A1 | Process for preparing levomilnacipran HCL | Cosma S.p.A. (IT) | 2014-11-26 | — | — | EP | claimed |
| US-20140343322-A1 | PROCESS FOR PREPARING LEVOMILNACIPRAN HCL | COSMA S.P.A. (IT) | 2014-11-20 | — | — | US | claimed |
| US-8865937-B2 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | Forest Laboratories Holding Limited (BM) | 2014-10-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343322-A1 | PROCESS FOR PREPARING LEVOMILNACIPRAN HCL | TNNT2, SSTR2, TNNC1 | SLC6A2 201/4885SLC6A4 179/4885KDM4E 776/4885 |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | SLC6A2 107/4885SLC6A4 81/4885KDM4E 4769/4885 |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | PNMT, SLC6A3, HTR3B | SLC6A2 11/4885SLC6A4 8/4885KDM4E 385/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | SLC6A2 27/4885SLC6A4 15/4885KDM4E 1049/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | SLC6A2 174/4885SLC6A4 86/4885KDM4E 2886/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | SLC6A2 105/4885SLC6A4 111/4885KDM4E 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.